{"product_id":"slu-pp-915-100-mg","title":"SLU-PP-915 100 mg – Experimental Metabolic Signaling Compound","description":"\u003ch3\u003eSLU-PP-915: Molecular Mechanism of Action and Preclinical Studies\u003c\/h3\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eSLU-PP-915 (chemical identifier: 2,5-disubstituted thiophene amide with boronic acid; CAS not specified in primary sources) is a synthetic, orally bioavailable pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ). It was developed through structure-based optimization of a new acyl hydrazide-derived chemical series at Saint Louis University, distinct from the earlier pan-ERR agonist SLU-PP-332. The key innovation is the incorporation of a boronic acid moiety, which replaces phenolic or aniline groups found in prior scaffolds. This modification enhances metabolic stability and maintains potent agonist activity across all three ERR isoforms (EC₅₀ values ≈ 414 nM for ERRα, 435 nM for ERRβ, and 378 nM for ERRγ).\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eNo human clinical trials have been conducted or reported as of April 2026. All available data are preclinical (in vitro cell assays, ex vivo tissues, and animal models). SLU-PP-915 remains an experimental research tool.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003ch3\u003eMolecular Mechanism of Action (MOA)\u003c\/h3\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eAt the molecular level, SLU-PP-915 functions as a direct ligand that binds the ligand-binding domain (LBD) of ERRs. Binding was validated using biophysical methods, including ¹H NMR protein-ligand titration experiments with the ERRγ LBD. The boronic acid group acts as a hydrogen-bond donor, stabilizing the receptor-ligand complex in a manner that mimics natural phenolic interactions in earlier agonists.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eLigand binding induces a conformational shift in the ERR LBD, promoting recruitment of coactivators such as PGC-1α. This activates ERR-dependent transcription at ERR response elements (ERREs) in promoter regions of target genes.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003ePrimary upregulated pathways include:\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e• Mitochondrial biogenesis and oxidative phosphorylation (OXPHOS): Induction of PPARGC1A (PGC-1α), electron transport chain components, and TCA cycle enzymes (e.g., Aco2, Sdhb).  \u003c\/div\u003e\n\u003cdiv\u003e• Fatty acid oxidation (FAO) and metabolic reprogramming: Upregulation of PDK4, ACSL1, CPT1B, and ACADM, shifting cellular energy utilization toward fatty acids and mitochondrial efficiency.  \u003c\/div\u003e\n\u003cdiv\u003e• Exercise-mimetic and stress-response genes: Induction of DDIT4 and LDHA.  \u003c\/div\u003e\n\u003cdiv\u003e• Autophagy and lysosomal biogenesis: Activation of TFEB, leading to increased expression of LAMP1, LAMP2, CTSD, MCOLN1, and p62\/SQSTM1, supporting autophagic flux and cellular maintenance.  \u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eERRγ appears to be a dominant mediator of these effects in cardiomyocytes and skeletal muscle, although the compound demonstrates balanced activity across all ERR isoforms. Genetic knockdown studies confirm that a large proportion of transcriptional changes induced by SLU-PP-915 are ERR-dependent, with ERRγ contributing significantly to metabolic pathway regulation.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eThe overall effect observed in experimental systems is a shift toward enhanced mitochondrial function, fatty acid oxidation, and cellular energy efficiency.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003ch3\u003ePreclinical Studies and Observed Effects\u003c\/h3\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e1. Exercise Capacity and Skeletal Muscle\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eIn controlled experimental models, SLU-PP-915 administration (oral and parenteral routes) was associated with measurable increases in endurance-related parameters, including running distance and duration in treadmill-based assays.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eGene expression analysis demonstrated induction of metabolic and mitochondrial pathways consistent with endurance adaptation. Chronic exposure in combination with training protocols further amplified oxidative and mitochondrial gene programs.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003ePharmacokinetic evaluations indicate improved oral bioavailability compared to earlier compounds in this class, supporting its use in research models examining systemic metabolic regulation.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e2. Cardiovascular Research Models\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eIn pressure-overload experimental models, SLU-PP-915 administration was associated with improvements in cardiac functional parameters, including left ventricular performance and metabolic gene expression profiles.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eObserved effects included:\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e• modulation of cardiac energy metabolism  \u003c\/div\u003e\n\u003cdiv\u003e• improved mitochondrial structure and function  \u003c\/div\u003e\n\u003cdiv\u003e• reduced markers associated with fibrotic remodeling  \u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eThese outcomes were strongly linked to ERRγ-mediated signaling pathways in cardiac tissue.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong\u003e3. Autophagy and Cellular Maintenance\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eIn cellular models, SLU-PP-915 exposure was associated with increased TFEB expression and activation of lysosomal and autophagy-related gene networks.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eThis translated to:\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e• enhanced autophagic flux  \u003c\/div\u003e\n\u003cdiv\u003e• increased lysosomal activity  \u003c\/div\u003e\n\u003cdiv\u003e• improved clearance of damaged cellular components  \u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eThese findings support its relevance in studies examining cellular maintenance, stress response, and metabolic adaptation.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003ch3\u003eTranslational Research Context (Allometric Models)\u003c\/h3\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eIn preclinical research, exposure frameworks are sometimes evaluated using allometric scaling approaches to compare biological responses across species.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eFor SLU-PP-915, experimental exposure ranges have been explored in controlled animal models to investigate metabolic, mitochondrial, and cardiovascular outcomes. These values are used exclusively for comparative and mechanistic research purposes.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eAll findings remain within preclinical contexts and are not intended to represent human application parameters.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003ch3\u003eComparative Research Context\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003ctable height=\"32\" style=\"width: 95.3405%;\" width=\"100%\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003e Parameter\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003eSLU-PP-332\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003eSLU-PP-915\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eChemical Scaffold\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003eAcyl hydrazide-based\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003e2,5-disubstituted thiophene amide with boronic acid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eKey Structural Feature\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003ePhenolic\/aniline groups\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003eBoronic acid moiety\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eOral Bioavailability\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003eLimited\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003eImproved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eMetabolic Stability\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003eLower\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003eHigher\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eERRα EC₅₀\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003e98 nM\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003e414 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eERRβ EC₅₀\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003e~230 nM\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003e435 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eERRγ EC₅₀\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003e~430 nM\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003e378 nM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003ePotency Profile\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003eERRα-preferring\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003eBalanced pan-ERR agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eExercise Model Effects\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003eIncreased endurance parameters\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003eComparable effects with improved exposure profile\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 41.2548%;\"\u003eCardiovascular Models\u003c\/td\u003e\n\u003ctd style=\"width: 31.4782%;\"\u003eImproved functional markers\u003c\/td\u003e\n\u003ctd style=\"width: 26.5066%;\"\u003eComparable metabolic and functional outcomes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3\u003eSummary\u003c\/h3\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eSLU-PP-915 is an orally active pan-ERR agonist studied in experimental models for its effects on metabolic regulation, mitochondrial function, fatty acid oxidation, and autophagy.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003ePreclinical studies demonstrate its role in modulating transcriptional programs associated with energy metabolism and cellular adaptation, with ERRγ playing a central role in mediating these effects.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003eAll available data remain within controlled laboratory and preclinical research contexts.\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003ch3 data-end=\"400\" data-start=\"376\" data-section-id=\"10kdm3j\"\u003e\u003cspan role=\"text\"\u003eResearch Overview\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp data-end=\"498\" data-start=\"402\"\u003eExplore the scientific context, signaling pathways, and experimental research behind SLU-PP-915:\u003c\/p\u003e\n\u003cp data-end=\"579\" data-start=\"500\"\u003e→ \u003ca href=\"https:\/\/www.peptideregenesis.com\/blogs\/peptide-blog\/what-is-slu-pp-915\"\u003eWhat is SLU-PP-915? – Molecular Mechanism and Metabolic Research Overview\u003c\/a\u003e\u003c\/p\u003e\n\u003cp data-end=\"579\" data-start=\"500\"\u003e\u003cspan style=\"font-kerning: none;\"\u003eExplore the molecular relationship between ERR activation, mitochondrial metabolism, and exercise-induced cellular adaptation.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-end=\"579\" data-start=\"500\"\u003e\u003cspan style=\"font-kerning: none;\"\u003e\u003cspan\u003e → \u003ca href=\"https:\/\/www.peptideregenesis.com\/blogs\/peptide-blog\/exercise-and-mitochondrial-health\"\u003eExercise \u0026amp; Mitochondrial Health Blog\u003c\/a\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cstrong data-start=\"645\" data-end=\"672\"\u003eRelated Research Topics\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003e\u003cbr\u003e\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cp data-start=\"459\" data-end=\"638\"\u003eFor a broader understanding of \u003cstrong data-start=\"490\" data-end=\"552\"\u003emetabolic energy pathways and performance-related research\u003c\/strong\u003e:\u003cbr data-start=\"553\" data-end=\"556\"\u003e→ \u003ca href=\"https:\/\/www.peptideregenesis.com\/blogs\/peptide-blog\/metabolic-energy-endurance-research\"\u003eMetabolic Energy Explained: Pathways, Fat Metabolism, and Performance Research\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PRG","offers":[{"title":"Default Title","offer_id":52711337394442,"sku":null,"price":290.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0908\/7113\/6522\/files\/slu-pp915_100mg_2.png?v=1773990584","url":"https:\/\/www.peptideregenesis.com\/products\/slu-pp-915-100-mg","provider":"PRG","version":"1.0","type":"link"}